AG˹ٷ

STOCK TITAN

[6-K] Biodexa Pharmaceuticals plc American Depositary Shs Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary
Riscrivi il seguente testo:
Reescribe el siguiente texto:
다음 텍스트를 다시 작성하세�:
Réécrivez le texte suivant :
Schreibe den folgenden Text um:
Positive
  • None.
Negative
  • None.
Riscrivi il seguente testo:
Reescribe el siguiente texto:
다음 텍스트를 다시 작성하세�:
Réécrivez le texte suivant :
Schreibe den folgenden Text um:
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2025

Commission File Number: 001-37652

Biodexa Pharmaceuticals PLC
(Translation of registrant's name into English)

1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

The information included in this report on Form 6-K, including Exhibit 99.1, shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File No. 333-214969) and Form F-3 (File No. 333-233901) of the Company (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

 


SUBMITTED HEREWITH: 

Exhibit Number   Description
     
99.1   Press Release dated July 31, 2025


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

        Biodexa Pharmaceuticals PLC    
    (Registrant)
     
   
Date: July 31, 2025       /s/ Stephen Stamp    
    Stephen Stamp
    Chief Executive Officer, Chief Financial Officer
   

  

 

FAQ

What information is available?

This document appears to contain limited substantive content.
Biodexa Pharmaceuticals plc

NASDAQ:BDRX

BDRX Rankings

BDRX Latest News

Jul 15, 2025
ADR Ratio Change

BDRX Latest SEC Filings

BDRX Stock Data

4.36M
499.16k
8.82%
29.86%
5.4%
Biotechnology
Healthcare
United Kingdom
Cardiff